

Company Update

Fineotex Chemical Ltd

Bloomberg Code: FTXC IN

India Research - Stock Broking

BUY

H1FY17 Performance in-line amidst Persisting Uncertainty: The company's consolidated revenue in H1FY17 has grown by 3.8% to Rs. 590 Mn as against Rs. 568 Mn in H1FY16. However, it has registered mild de-growth by -0.8% QoQ basis wherein revenue de-grew to Rs. 294 Mn from Rs. 296 Mn. The mild de-growth has been on account of currency exchange rate fluctuations loss occurred during the aforesaid quarters and lower demand for high value added products due to seasonal effect. The company has witnessed improvement in its volume growth about 5% to 8% during the QoQ basis. Nonetheless, we have revised our estimates downside keeping in view tightened liquidity situation which has arisen following de-monetization of Rs.1000 and Rs.500 currency notes which may result into contracting manufacturing activities during upcoming quarters. The company's major focus on value added product will enhance appeal of its product basket offerings. We expect that going forward, earnings of the company will register stable top-line growth at CAGR of 6.6% during FY16-18E which will have overall positive bearing on bottom-line in view of focus on margin based products and also with likely improvements in macro-economic environment.

Improved Margin Performance: The company's gross margin/EBITDA margin and PAT margin have grown by 454bps/149bps/402bps YoY basis and 132bps/105bps/321bps QoQ basis to 41.5%/23.4%/18.0% during Q2FY17, respectively on account of high margin business growth. The improvements in margins have been supported by lower other expenses, lower finance cost and higher other income. We expect that margin trend likely to continue going forward and the company to maintain EBITDA margin around 24% and PAT Margin of around 16%.

Valuation and Outlook

We continue with our earlier positive long term outlook on the company and recommend "BUY" on stock for an upwardly revised target price of Rs. 34.7 which represents to an upside of 22.5%. At CMP of Rs. 28.3, the stock is trading at P/Ex of 15.8 of its FY18E EPS of Rs. 1.8. We are positive on the back of constant focus on value added products will drive the revenue to healthy return ratios i.e., RoE/RoCE of over 18%/20%, EBITDA margin of over 24%, Zero debt and continuous dividend payment.

Exhibit 1: Valuation Summary

YE Mar (Rs. Mn)	FY14	FY15	FY16	FY17E	FY18E
Net Sales	867	1020	1087	1142	1236
EBITDA	92	165	265	281	308
EBITDA Margin (%)	10.7	16.2	24.4	24.6	24.9
Adj. Net Profit	65	129	170	183	201
EPS (Rs.)	0.6	1.2	1.5	1.6	1.8
RoE (%)	10.6	18.3	20.3	19.0	18.4
PE (x)	10.2	19.4	21.3	17.4	15.8

Source: Company, Karvy Research; *Represents multiples for FY14, FY15 & FY16 are based on historic market price

For private circulation only. For important information about Karvy's rating system and other disclosures refer to the end of this material. **Karvy Stock Broking Research is also available on Bloomberg, KRVY<GO>**, Thomson Publishers & Reuters

Recommendation (Rs.)

CMP	28.3
Target Price	34.7
Previous Target Price	33.0
Upside (%)	22.5

Stock Information

Mkt Cap (Rs.mn/US\$ mn)	3161 / 46
52-wk High/Low (Rs.)	41 / 20
3M Avg. daily volume (mn)	0.4
Beta (x)	1.3
Sensex/Nifty	25860 / 7966
O/S Shares(mn)	112.3
Face Value (Rs.)	2.0

Shareholding Pattern (%)


Promoters	71.72
FIIIs	0.00
DIIIs	0.03
Others	28.25

Stock Performance (%)

	1M	3M	6M	12M
Absolute	(16)	6	(6)	12
Relative to Sensex	(9)	14	(9)	11

Source: Bloomberg

Relative Performance*



Source: Bloomberg; *Index 100

Earnings Revision (%)

YE Mar	FY17E	FY18E
Sales (%)	↓ (2.8)	↔ 0.0
EBITDA (%)	↓ (2.9)	↑ 0.2
PAT (%)	↓ (2.3)	↑ 0.5

Source: Karvy Research;

Analyst Contact


Kishor Kumar
 040 - 3321 6277
 kishor.kumar@karvy.com

Exhibit 2: Q2FY17

YE Mar (Rs. Mn)	Q2FY17	Q1FY17	QoQ %	Q2FY16	YoY %	H1FY17	H1FY16	YoY %
Turnover	294	296	(0.8)	314	(6.6)	590	568	3.8
Expenditure	225	230	(2.1)	245	(8.3)	455	442	3.0
EBITDA	69	66	3.9	69	(0.2)	135	126	6.7
Depreciation	2	1	10.4	1	28.5	3	3	18.0
Interest	1	1	(9.6)	1	6.3	2	2	(14.6)
Other Income	16	7	138.2	8	98.3	22	14	55.9
PBT	82	70	16.4	75	9.6	152	136	11.9
Tax	21	20	4.0	23	(6.8)	42	42	(1.2)
PAT	53	44	20.7	44	20.3	97	80	20.2
EBITDA Margin (%)	23.4	22.3	105 bps	21.9	149 bps	22.8	22.2	60 bps
EBIT Margin(%)	28.1	24.0	409 bps	24.0	414 bps	26.1	24.3	179 bps
Net Profit Margin (%)	18.0	14.8	321 bps	14.0	402 bps	16.4	14.2	223 bps


Source: Company, Karvy Research

Exhibit 3: Quarterly Revenue Trend & Revenue growth




Source: Company, Karvy Research

Exhibit 4: Raw Material as % of sales (%)




Source: Company, Karvy Research

Exhibit 5: Quarterly Gross Margin Trend (%)




Source: Company, Karvy Research

Exhibit 6: Quarterly EBITDA & EBITDA margin (%)




Source: Company, Karvy Research

Exhibit 7: Quarterly PAT & PAT margin (%) Trend




Source: Company, Karvy Research

Exhibit 8: Quarterly Effective tax rate Trend (%)



Source: Company, Karvy Research

Exhibit 9: Quarterly Margins Trend (%)


Source: Company, Karvy Research

Key Takeaways of Conference Call:

Revenue Analysis: FCL experienced revenue growth at 3.8% in H1FY17 YoY basis from Rs.568 mn to Rs. 590 Mn due to better performance of advance specialty chemicals. However, it recorded flattish growth of -0.8% QoQ basis from Rs.296 mn to Rs. 294 Mn during the quarter on account of currency exchange fluctuation loss and lower demand for high value added products due to seasonal effect. We expect that focus on more advanced chemicals like eco-friendly non-toxic products that kill mosquito life cycle, expanding geographic wings (point in case is the company entering into Iran engaging with 4 agents), increase distributors list from 68 in Q1FY17 to 74 in Q2FY17 with sole selling policy to channelize its efforts in view of long term relationship which will support the topline growth at CAGR of 6.6% during FY16-18E.

EBITDA Analysis: FCL's EBITDA rose at 3.9% on QoQ basis to Rs. 69 Mn in Q2FY17 as against Rs. 66 Mn in Q1FY17 and it grew 6.7% YoY basis in H1FY17 when compared with H1FY16. EBITDA margin increased by 149 bps YoY and 105 bps QoQ. The company has reported 23.4% EBITDA margin in Q2FY17 on support from innovate advance specialty chemicals which require less raw material. Its other expenses as a percentage of sales have increased by 198 bps YoY and 41 bps QoQ to Rs. 43 Mn due to promotional activities in Q2FY17.

PAT Analysis: Lower finance cost, lower tax and higher other income aided profits during the quarter. Lower finance costs were mainly due to no debt taken during the quarter. Higher other income has been generated with higher investment in mutual funds, dividend etc. Effective tax rate was lower at 26.1% in Q2FY17 from 29.2% in Q1FY17. Finally, the company reported PAT growth at 20.3% YoY to Rs. 53 Mn during Q2FY17 which has been in-line with our estimates.


Change in Estimates: We have revised our revenue estimates down by ~2.8% due to demonetization of Rs.1000 and Rs.500 currency notes which has potential of adversely impacting production and demand of textile products in the short run where there is greater application of the company's products. However, we maintain our positive outlook with likely revenue growth of 8.3% YoY to Rs. 1236 Mn during FY18E. We have revised our EBITDA estimates down for FY17E from Rs. 289 Mn to Rs. 281Mn, implying to -2.9%. While we have maintained our EBITDA for FY18E at the same level of Rs. 308 Mn on the back of softening of crude oil prices (i.e., 20% raw material based on crude oil price) and enhanced value chain contributing higher products which require lower raw materials. Thus, PAT estimates for FY17E have been revised down by 2.3% from Rs. 187 Mn to Rs. 183 Mn. While PAT estimates for FY18E have been revised up from Rs. 200 Mn to Rs. 201 Mn, implying to 0.5%.

Exhibit 10: Change in Estimates

YE Mar (Rs. Mn)	FY17E			FY18E		
	Old	New	% Change	Old	New	% Change
Net Sales	1175	1142	(2.8)	1236	1236	0.0
EBITDA	289	281	(2.9)	307	308	0.2
EBITDA Margin (%)	24.6	24.6	(2) bps	24.8	24.9	7 bps
Adj. Net Profit	187	183	(2.3)	200	201	0.5
EPS (Rs.)	1.69	1.63	(3.8)	1.78	1.79	0.4

Source: Company, Karvy Research

Exhibit 11: PE Band



Source: BSE, Karvy Research

Upcoming Event: The company has announced buy back of shares in open market around 0.89% of total outstanding 112.3 Mn shares at the face value of Rs. 2 (not exceeding 9,98,110 no. of shares) at a price not exceeding Rs. 40 (including premium of Rs. 38 per equity share) which is payable in cash amount of upto Rs. 39.9 Mn. We have factored share reduction on account of buyback in our estimates.

Financials

Exhibit 12: Income Statement

YE Mar (Rs. Mn)	FY14	FY15	FY16	FY17E	FY18E
Revenues	867	1020	1087	1142	1236
Growth (%)	(9.6)	17.7	6.6	5.0	8.3
Operating Expenses	774	855	822	861	929
EBITDA	92	165	265	281	308
Growth (%)	10.7	16.2	24.4	24.6	24.9
Depreciation & Amortization	3	5	6	8	11
Other Income	28	45	33	35	38
EBIT	118	205	292	307	334
Interest Expenses	4	3	4	3	0
PBT	112	202	289	304	334
Tax	33	56	91	96	106
Adjusted PAT	65	129	170	183	201
Growth (%)	(7.6)	98.7	31.9	7.2	10.0

Source: Company, Karvy Research

Exhibit 13: Balance Sheet

YE Mar (Rs. Mn)	FY14	FY15	FY16	FY17E	FY18E
Cash & Cash Equivalents	127	100	95	96	134
Trade Receivables	219	217	254	250	271
Inventory	114	104	115	114	122
Loans & Advances & Others	184	177	158	160	163
Investments	158	293	390	421	484
Net Block	76	117	131	203	271
Total Assets	879	1008	1142	1244	1446
Current Liabilities & Provisions	147	166	145	156	166
Debt	7	10	30	0	0
Other Liabilities	77	69	53	79	106
Total Liabilities	231	244	229	235	273
Shareholders Equity	112	225	225	223	223
Reserves & Surplus	535	539	688	787	951
Total Networth	648	763	913	1009	1173
Total Networth & Liabilities	879	1008	1142	1244	1446

Source: Company, Karvy Research

Exhibit 14: Cash Flow Statement

YE Mar (Rs. Mn)	FY14	FY15	FY16	FY17E	FY18E
PBT	112	202	289	304	334
Depreciation	3	5	6	8	11
Interest	4	3	0	3	0
Tax Paid	(26)	(43)	(102)	(96)	(106)
Inc/dec in Net WC	(59)	4	(42)	13	(21)
Other Income	(25)	(43)	(14)	(35)	(38)
Other non cash items	1	(9)	(30)	0	0
Cash flow from operating activities	9	120	106	197	180
Inc/dec in capital expenditure	(7)	(52)	(15)	(80)	(80)
Inc/dec in investments	142	(97)	(87)	(31)	(63)
Others	(16)	25	5	35	38
Cash flow from investing activities	119	(124)	(98)	(76)	(105)
Inc/dec in borrowings	(28)	(19)	20	(30)	0
Dividend paid	(6)	(6)	(35)	(37)	(37)
Interest paid	(4)	(3)	(0)	(3)	0
Cash flow from financing activities	(38)	(28)	(15)	(110)	(37)
Net change in cash	90	(32)	(6)	11	38

Source: Company, Karvy Research

Exhibit 15: Key Ratios

YE Mar	FY14	FY15	FY16	FY17E	FY18E
EBITDA Margin (%)	10.7	16.2	24.4	24.6	24.9
EBIT Margin (%)	13.6	20.1	26.9	26.9	27.0
Net Profit Margin (%)	7.5	12.7	15.7	16.0	16.3
Dividend Payout Ratio (%)	17.3	8.7	19.7	18.4	16.8
Net Debt/Equity (x)	(0.2)	(0.1)	(0.1)	(0.1)	(0.1)
RoE (%)	10.6	18.3	20.3	19.0	18.4
RoCE (%)	12.2	19.5	22.0	20.2	19.4

Source: Company, Karvy Research


Exhibit 16: Valuation Parameters

YE Mar	FY14	FY15	FY16	FY17E	FY18E
EPS (Rs.)	0.6	1.2	1.5	1.6	1.8
DPS (Rs.)	0.1	0.1	0.3	0.3	0.3
BVPS (Rs.)	5.8	6.8	8.1	9.0	10.4
PE (x)	10.2	19.4	21.3	17.4	15.8
P/BV (x)	1.0	3.3	4.0	3.1	2.7
EV/EBITDA (x)	6.4	15.0	13.7	11.2	10.2
EV/Sales (x)	0.7	2.4	3.3	2.8	2.5

Source: Company, Karvy Research; *Represents multiples for FY14, FY15 & FY16 are based on historic market price

Stock Ratings	Absolute Returns
Buy	: > 15%
Hold	: 5-15%
Sell	: <5%

Connect & Discuss More at

 1800 419 8283 (Toll Free)

 research@karvy.com

 Live Chat



Disclaimer

- **Analyst certification:** The following analyst(s), **Kishor Kumar**, who is (are) primarily responsible for this report and whose name(s) is/are mentioned therein, certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.
- **Disclaimer:** Karvy Stock Broking Limited [KSBL] is registered as a research analyst with SEBI (Registration No INH200003265). KSBL is also a SEBI registered Stock Broker, Depository Participant, Portfolio Manager and also distributes financial products. The subsidiaries and group companies including associates of KSBL provide services as Registrars and Share Transfer Agents, Commodity Broker, Currency and forex broker, merchant banker and underwriter, Investment Advisory services, insurance repository services, financial consultancy and advisory services, realty services, data management, data analytics, market research, solar power, film distribution and production, profiling and related services. Therefore associates of KSBL are likely to have business relations with most of the companies whose securities are traded on the exchange platform. The information and views presented in this report are prepared by Karvy Stock Broking Limited and are subject to change without any notice. This report is based on information obtained from public sources, the respective corporate under coverage and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KSBL. While we would endeavor to update the information herein on a reasonable basis, KSBL is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent KSBL from doing so. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KSBL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. This material is for personal information and we are not responsible for any loss incurred based upon it. The investments discussed or recommended in this report may not be suitable for all investors. Investors must make their own investment decisions based on their specific investment objectives and financial position and using such independent advice, as they believe necessary. While acting upon any information or analysis mentioned in this report, investors may please note that neither KSBL nor any associate companies of KSBL accepts any liability arising from the use of information and views mentioned in this report. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Past performance is not necessarily a guide to future performance. Forward-looking statements are not predictions and may be subject to change without notice. Actual results may differ materially from those set forth in projections.
- Associates of KSBL might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.
- Associates of KSBL might have received compensation from the subject company mentioned in the report during the period preceding twelve months from the date of this report for investment banking or merchant banking or brokerage services from the subject company in the past twelve months or for services rendered as Registrar and Share Transfer Agent, Commodity Broker, Currency and forex broker, merchant banker and underwriter, Investment Advisory services, insurance repository services, consultancy and advisory services, realty services, data processing, profiling and related services or in any other capacity.
- KSBL encourages independence in research report preparation and strives to minimize conflict in preparation of research report.
- Compensation of KSBL's Research Analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.
- KSBL generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.
- KSBL or its associates collectively or Research Analysts do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.
- KSBL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report and have no financial interest in the subject company mentioned in this report.
- Accordingly, neither KSBL nor Research Analysts have any material conflict of interest at the time of publication of this report.
- It is confirmed that KSBL and Research Analysts, primarily responsible for this report and whose name(s) is/ are mentioned therein of this report have not received any compensation from the subject company mentioned in the report in the preceding twelve months.
- It is confirmed that **Kishor Kumar**, Research Analyst did not serve as an officer, director or employee of the companies mentioned in the report.
- KSBL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
- Neither the Research Analysts nor KSBL have been engaged in market making activity for the companies mentioned in the report.
- We submit that no material disciplinary action has been taken on KSBL by any Regulatory Authority impacting Equity Research Analyst activities.

Karvy Stock Broking Limited

Plot No.31, 6th Floor, Karvy Millennium Towers, Financial District, Nanakramguda, Hyderabad, 500 032, India

Tel: 91-40-2331 2454; Fax: 91-40-2331 1968

For More updates & Stock Research, visit www.karvyonline.com